J Korean Med Sci.  2010 Nov;25(11):1626-1632. 10.3346/jkms.2010.25.11.1626.

Exendin-4 Protects Oxidative Stress-Induced beta-Cell Apoptosis through Reduced JNK and GSK3beta Activity

• Kim JY
• Lim DM
• Moon CI
• Jo KJ
• Lee SK
• Baik HW
• Lee KH
• Lee KW
• Park KY
• Kim BJ

• KMID: 1779233
• DOI: http://doi.org/10.3346/jkms.2010.25.11.1626

Abstract

Oxidative stress induced by chronic hyperglycemia in type 2 diabetes plays a crucial role in progressive loss of beta-cell mass through beta-cell apoptosis. Glucagon like peptide-1 (GLP-1) has effects on preservation of beta-cell mass and its insulin secretory function. GLP-1 possibly increases islet cell mass through stimulated proliferation from beta-cell and differentiation to beta-cell from progenitor cells. Also, it probably has an antiapoptotic effect on beta-cell, but detailed mechanisms are not proven. Therefore, we examined the protective mechanism of GLP-1 in beta-cell after induction of oxidative stress. The cell apoptosis decreased to ~50% when cells were treated with 100 microM H2O2 for up to 2 hr. After pretreatment of Ex-4, GLP-1 receptor agonist, flow cytometric analysis shows 41.7% reduction of beta-cell apoptosis. This data suggested that pretreatment of Ex-4 protect from oxidative stress-induced apoptosis. Also, Ex-4 treatment decreased GSK3beta activation, JNK phosphorylation and caspase-9, -3 activation and recovered the expression of insulin2 mRNA in beta-cell lines and secretion of insulin in human islet. These results suggest that Ex-4 may protect beta-cell apoptosis by blocking the JNK and GSK3beta mediated apoptotic pathway.

Keyword

Apoptosis; Exendin-4; Glucagon-Like Peptide 1; Oxidative Stress; Insulin-Secreting Cells

MeSH Terms

Animals
*Apoptosis
Caspase 3/metabolism
Caspase 9/metabolism
Cells, Cultured
Cricetinae
Flow Cytometry
Glucagon-Like Peptide 1/pharmacology
Glycogen Synthase Kinase 3/*metabolism
Humans
Hydrogen Peroxide/toxicity
Insulin/genetics/metabolism
Insulin-Secreting Cells/drug effects/*enzymology/metabolism
JNK Mitogen-Activated Protein Kinases/*metabolism
*Oxidative Stress
Peptides/*pharmacology
Phosphorylation
Receptors, Glucagon/agonists/metabolism
Signal Transduction
Venoms/*pharmacology

Figure

• 

  Fig. 1 Effects of the NAC or Ex-4 on oxidative stress-induced apoptosis. HIT-T15 cells were pretreated NAC (5 mM) or Ex-4 (25 nM), for 1 hr before stress induction. (A) After exposure to 100 µM H2O2, HIT-T15 cells apoptosis increased by time. Cells viability was measured with the MTT reduction assay. (B) After treatment of H2O2 (100 µM, 2 hr), effects of the NAC or Ex-4 on cell viability were measured by MTT reduction assay. (C) H2O2 (100 µM, 4 hr)-induced apoptotic nuclei reduced via NAC or Ex-4. Photographs were taken using a blue filter at a magnification of ×400. (D) Flow cytometric analysis of apoptosis of HIT-T15 cells exposed to H2O2 (100 µM, 8 hr). Apoptotic cells were measured by FACS analysis after Annexin V/PI staining. FL1: Annexin V-FITC, FL2: PI. Data are shown as the means±SE of six independent experiments. *P<0.001 vs control cells; †P<0.001 vs H2O2 alone.

• 

  Fig. 2 Protective effect of Ex-4 on oxidative stress-induced apoptosis via PI3-kinase/Akt/GSK3β and JNK signaling pathway in human islet. Human islet was pretreated with H89 (PKA inhibitor, 10 µM) or SP600125 (JNK inhibitor, 20 µM). After 30 min, human islet was treated Ex-4 (25 nM), NAC (5 mM) or forskolin (20 µM), for 1 hr before stress induction. After treatment of H2O2 (100 µM, 2 hr), (A) In oxidative stress condition, expression change of total Akt, GSK3β, JNK, phospho-Akt (Ser 473), phospho-GSK3β (Ser-9) and phospho-JNK were assessed by western blot. (B) Total JNK, GSK3β, phospho-GSK3β (Ser-9) and phospho-JNK were detected in the absence or presence of SP600125. These results are representative of three independent experiments.

• 

  Fig. 3 Protective effect of Ex-4 on caspase-8, 9, and -3 activity in oxidative stress-induced apoptosis. HIT-T15 cells were pretreated with H89 (PKA inhibitor, 10 µM). After 30 min, HIT-T15 cells were treated Ex-4 (25 nM) or NAC (5 mM), for 1 hr before stress induction. After treatment of H2O2 (100 µM, 2 hr), (A) Cell lysates were incubated with IETD-pNA, LEHD-pNA and DEVD-pNA for in vitro caspase-8, -9, and -3, respectively. The caspase-8, -9, and -3 activity were measured by the colorimetric assay. (B) Active form of capase-9 and -3 were detected using western blot analysis. Data are shown as the means±S.E. of three independent experiments. *P<0.01 vs control cells; †P<0.01 vs H2O2 alone; ‡P<0.01 vs Ex-4 or NAC in treated H2O2.

• 

  Fig. 4 Effects of the Ex-4 on insulin secretion. Human islet was pretreated with H89 (10 µM). After 30 min, HIT-T15 cells or human islet was treated Ex-4 (25 nM) and NAC (5 mM) for 1 hr before stress induction. After treatment of H2O2 (100 µM, 2 hr), (A) Expression levels of insulin2 mRNA were examined by real time RT-PCR in HIT-T15 cells. Data were expressed as the rates to the expression levels to GAPDH in the same sample. GAPDH used for loading control. (B) Insulin secretion in human islet was detected by Insulin ELISA kit. Data are shown as the means±S.E. of four independent experiments. *P<0.01 vs H2O2 alone; †P<0.01 vs Ex-4 in treated H2O2.

Reference

1. Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patanè G, Laybutt R, Bonner-Weir S, Weir GC. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem. 1999. 274:14112–14121.

2. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord. 2008. 9:329–343.

3. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000. 23:1084–1091.

4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001. 414:813–820.

5. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002. 23:599–622.

6. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death. Science. 2005. 307:380–384.

7. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am. 1996. 25:255–270.

8. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001. 17:189–212.

9. Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Matsuhisa M, Yamasaki Y. Oxidative stress and the JNK pathway in diabetes. Curr Diabetes Rev. 2005. 1:65–72.

10. Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Miyatsuka T, Matsuhisa M, Yamasaki Y. Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. J Mol Med. 2005. 83:429–439.

11. Kaneto H, Xu G, Fujii N, Kim S, Bonner-Weir S, Weir GC. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem. 2002. 277:30010–30018.

12. Tuttle RL, Gill NS, Pugh W, Lee JP, Koeberlein B, Furth EE, Polonsky KS, Naji A, Birnbaum MJ. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med. 2001. 7:1133–1137.

13. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest. 2001. 108:1631–1638.

14. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995. 378:785–789.

15. Mussmann R, Geese M, Harder F, Kegel S, Andag U, Lomow A, Burk U, Onichtchouk D, Dohrmann C, Austen M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem. 2007. 282:12030–12037.

16. Liu Z, Tanabe K, Bernal-Mizrachi E, Permutt MA. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. Diabetologia. 2008. 51:623–631.

17. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007. 113:546–593.

18. Park IB. New and emerging drugs in type 2 diabetes. Korean J Med. 2007. 72:446–450.

19. Kim BJ. Stimulation of glucagon like peptide-1 secretion in enteroendocrine L cells. Korean Diabetes J. 2009. 33:458–463.

20. Kim JY, Lee SK, Baik HW, Lee KH, Kim HJ, Park KS, Kim BJ. Protective effects of glucagon like peptide-1 on HIT-T15 beta cell apoptosis via ER stress induced by 2-deoxy-D-glucose. Korean Diabetes J. 2008. 32:477–487.

21. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000. 343:230–238.

22. Steensma DP, Timm M, Witzig TE. Flow cytometric methods for detection and quantification of apoptosis. Methods Mol Med. 2003. 85:323–332.

23. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002. 7:313–319.

24. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest. 2008. 118:3378–3389.

25. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001. 359:1–16.

26. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000. 275:10761–10766.

27. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001. 78:1219–1232.